Novel antiglaucoma prodrugs and codrugs of ethacrynic acid

Bioorg Med Chem Lett. 2005 Aug 1;15(15):3524-7. doi: 10.1016/j.bmcl.2005.05.128.

Abstract

The purpose of this study was to synthesize a novel prodrug of ethacrynic acid (ECA) with short chain polyethylene glycols (PEGs) and codrugs of ECA with the beta-adrenergic blocking agent atenolol (ATL) or timolol (TML) to overcome the adverse effects of ECA and to enhance its physicochemical properties.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / chemical synthesis*
  • Adrenergic beta-Antagonists / pharmacology
  • Atenolol / pharmacology
  • Ethacrynic Acid / adverse effects
  • Ethacrynic Acid / chemical synthesis*
  • Ethacrynic Acid / pharmacology
  • Ethacrynic Acid / therapeutic use
  • Glaucoma / drug therapy*
  • Polyethylene Glycols / chemistry
  • Prodrugs / chemical synthesis*
  • Prodrugs / pharmacology
  • Prodrugs / therapeutic use
  • Timolol / pharmacology

Substances

  • Adrenergic beta-Antagonists
  • Prodrugs
  • Polyethylene Glycols
  • Atenolol
  • Timolol
  • Ethacrynic Acid